Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
Stocks in this Quantisnow insightHealth Care
Historical context for TTRX
Across the 18 sessions after earlier TTRX headlines, the stock closed higher 5 times and lower 13 times, with a median move of 4.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TTRX | SPY |
|---|---|---|---|
| May 27, 2026 | Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model | -1.3% | -0.0% |
| May 19, 2026 | Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 | -7.1% | -0.7% |
| May 18, 2026 | Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead | +21.0% | -0.1% |
| May 12, 2026 | Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates | +2.6% | -0.2% |
| Apr 1, 2026 | Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates | -2.7% | +0.8% |
| Mar 24, 2026 | Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group | -2.3% | -0.3% |
Quantisnow market dataNASDAQ
TTRX
Turn Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for TTRX
Full TTRX profile on Quantisnow Follow TTRX and get a push notification the moment its next story breaks.